Cardinal Capital Management Raises Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Cardinal Capital Management increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,125 shares of the medical instruments supplier’s stock after purchasing an additional 535 shares during the period. Cardinal Capital Management’s holdings in Becton, Dickinson and Company were worth $6,540,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Sound Income Strategies LLC boosted its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Opal Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company in the 2nd quarter worth approximately $45,000. Abound Wealth Management grew its position in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares in the last quarter. Tributary Capital Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $49,000. Finally, Chilton Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on BDX. Stifel Nicolaus raised their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James reduced their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Trading Up 0.0 %

Shares of NYSE BDX opened at $240.32 on Friday. The stock has a market capitalization of $69.45 billion, a P/E ratio of 52.93, a PEG ratio of 1.79 and a beta of 0.42. The stock’s 50 day moving average price is $236.86 and its two-hundred day moving average price is $235.28. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $262.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.96 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date was Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.